23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
20:08 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC) by 50% for up to six years in the retrospective real-world SYROS study in patients...
04:24 , Oct 25, 2018 |  BC Extra  |  Preclinical News

Inhibiting metabolic enzyme to prevent NAFLD, acute kidney injury

TES Pharma s.r.l. (Perugia, Italy) is developing small molecule inhibitors of a metabolic enzyme that limits NAD+ production after the metabolic and cancer company and the Swiss Federal Institute of Technology Lausanne (EPFL) showed a...
03:20 , Aug 17, 2018 |  BC Week In Review  |  Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
14:02 , Aug 14, 2018 |  BC Extra  |  Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
18:17 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and fruit fly studies suggest promoting NAD + synthesis could help treat PD caused by GBA mutations. In neurons generated via induced pluripotent stem (iPS) cells from a patient...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
22:46 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Ischemia / reperfusion injury Mouse studies suggest nicotinamide mononucleotide (NMN) or hydrogen sulfide could help treat ischemia. In a mouse model of injury-induced ischemia, the NAD+ precursor NMN increased blood flow and muscle capillary...
19:09 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Santhera's idebenone misses in Phase I/II for primary progressive MS

Santhera Pharmaceuticals Holding AG (SIX:SANN) said idebenone (SNT-MC17) missed the primary endpoint in an NIH-sponsored Phase I/II trial to treat primary progressive multiple sclerosis (PPMS). In 66 evaluable patients, a once-daily 2,250 mg dose of...